Full Text View
Tabular View
No Study Results Posted
Related Studies
Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS
This study is currently recruiting participants.
Verified by University Magna Graecia, April 2007
First Received: April 13, 2007   Last Updated: April 25, 2007   History of Changes
Sponsor: University Magna Graecia
Information provided by: University Magna Graecia
ClinicalTrials.gov Identifier: NCT00461643
  Purpose

Anovulatory infertility is a common feature of the polycystic ovary syndrome (PCOS). Even if several first-step treatments have been proposed for anovulatory infertile PCOS patients, very few data are available in literature regarding the best integrated strategy. In fact, a single compound could be effective as first-step approach but not or less useful when integrated in a more complex strategy.

The goal of the current protocol will be to compare three different strategies for treating anovulatory infertility in PCOS patients having as primary end-point the multiple pregnancy rate.


Condition Intervention Phase
Anovulatory Infertility Related to Polycystic Ovary Syndrome
Drug: Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study
Official Title: Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial

Resource links provided by NLM:


Further study details as provided by University Magna Graecia:

Primary Outcome Measures:
  • Multiple pregnancy rate

Secondary Outcome Measures:
  • Ovulation rate
  • Pregnancy rate
  • Abortion rate
  • Live-birth rate
  • Adverse-events

Estimated Enrollment: 552
Study Start Date: January 2007
Estimated Study Completion Date: October 2009
Detailed Description:

All patients eligible will undergo baseline assessment consisting of antropometric, hormonal, and ultrasonographic assessments. Successively, patients enrolled will be allocated in three different strategies (strategy A, B, and C).

A total of 184 infertile PCOS patients per arm will be enrolled and treated with three different integrated strategies: clomiphene followed by clomiphene plus metformin followed by gonadotropins (strategy A); metformin followed by metformin plus clomiphene followed by gonadotropins(strategy B); and metformin plus clomiphene followed by gonadotropins(strategy C).

In all patients, the same regimen will be used to administered clomiphene, metformin, and gonadotropins.Both clomiphene and metformin will be administered at incremental doses in each case.Gonadotropins will be administrated to obtain a controlled ovarian stimulation using highly purified urinary FSH in a low-dose step-up protocol.

During the study, the clinical and reproductive outcomes, and adverse experiences will be evaluated in each woman.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Polycystic ovary syndrome (using ESHRE/ARSM 2004 criteria)

Exclusion Criteria:

  • Age <18 or >35 years
  • Severe obesity (BMI >35)
  • Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses
  • Hypothyroidism, hyperprolactinemia, Cushing’s syndrome, and non-classical congenital adrenal hyperplasia
  • Current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, antidiabetic and anti-obesity drugs or other hormonal drugs
  • Previous use of ovulation induction agents
  • Intention to start a diet or a specific program of physical activity
  • No uterine bleeding after progesterone challenge test
  • Organic pelvic diseases
  • Previous pelvic surgery
  • Suspected peritoneal factor infertility
  • Tubal or male factor infertility or sub-fertility
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00461643

Contacts
Contact: Stefano Palomba, MD +39-0961.883234 stefanopalomba@tin.it

Locations
Italy
"Pugliese" Hospital Recruiting
Catanzaro, Italy, 88100
Contact: Ingrid Tomaino, MD     +39 0961 883234     angela.falbo@libero.it    
Principal Investigator: Stefano Palomba, MD            
"Pugliese" Hospital Recruiting
Catanzaro, Italy, 88100
Contact: Ingrid Tomaino, MD     +39 0961 883234     zullo@unicz.it    
Principal Investigator: Stefano Palomba, MD            
Principal Investigator: Francesco Orio, MD            
Principal Investigator: Achille Tolino, MD            
Principal Investigator: Pasquale Mastrantonio, MD            
Principal Investigator: Brian Dale, MD            
Principal Investigator: Ettore Cittadini, MD            
Principal Investigator: Andrea Riccardo Genazzani, MD            
Pugliese-Ciaccio Hospital Recruiting
Catanzaro, Italy, 88100
Contact: , MD            
Sponsors and Collaborators
University Magna Graecia
Investigators
Principal Investigator: Stefano Palomba, MD Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro
  More Information

Publications:
Study ID Numbers: 01/2007
Study First Received: April 13, 2007
Last Updated: April 25, 2007
ClinicalTrials.gov Identifier: NCT00461643     History of Changes
Health Authority: Italy: The Italian Medicines Agency

Keywords provided by University Magna Graecia:
Anovulation
Clomiphene citrate
Infertility
Metformin
PCOS
RCT
Treatment

Additional relevant MeSH terms:
Infertility
Molecular Mechanisms of Pharmacological Action
Gonadal Disorders
Hormone Antagonists
Physiological Effects of Drugs
Hematologic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Clomiphene
Reproductive Control Agents
Ovarian Diseases
Selective Estrogen Receptor Modulators
Genital Diseases, Female
Estrogen Receptor Modulators
Hypoglycemic Agents
Pathologic Processes
Syndrome
Therapeutic Uses
Estrogen Antagonists
Disease
Anticoagulants
Citric Acid
Metformin
Endocrine System Diseases
Cysts
Genital Diseases, Male
Pharmacologic Actions
Adnexal Diseases
Neoplasms
Fertility Agents, Female
Fertility Agents

ClinicalTrials.gov processed this record on February 08, 2010